The odds that Amylyx Pharmaceuticals wins approval from the Food and Drug Administration for Albrioza, its treatment for ALS, have increased significantly over the past two weeks. My prediction: The FDA grants accelerated approval to Albrioza, with the requirement that Amylyx confirm the drug’s benefit for patients with results from the ongoing Phase 3 study — data expected in 2024.
I’m capable of making a positive prediction occasionally. I’m not all doom and gloom. This one feels right, with echoes of how the FDA acted on eteplirsen, the Duchenne muscular dystrophy drug, in 2016, and more recently, Biogen’s Alzheimer’s treatment Aduhelm, in 2021.
Continue to STAT+ to read the full story…
Click this link for the original source of this article.
Author: Adam Feuerstein
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
